Xvivo Perfusion Publishes Q3 2026 Earnings Call Transcript
Bitget2026/10/22 13:20- Xvivo Perfusion held its Q3 2026 earnings call on October 22 with CEO Christoffer Rosenblad and CFO Kristoffer Nordstrom.
- Net sales reached SEK 253 million, representing 32% organic growth; EBITDA rose to SEK 52 million from SEK 36 million.
- Management targets a US Heart Assist Transport launch in late 2027, followed by Liver Assist in early 2028, subject to regulatory clearance.
- Sales force investments for the US heart and liver launches are expected to cause a slight margin decline in the second half of 2027.
- Kidney growth could reach around 30% in 2027, but component shortages will prevent the business from meeting full market demand.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel’s weak performance puts pressure on chip stocks
BUZZ - Illumina shares fall due to third-quarter revenue missing expectations
Philippine Peso: Official jawboning slows depreciation – OCBC
Short-seller Eisman questions whether Anthropic "deliberately" concealed its latest financial report, AI safety narrative faces credibility crisis
Well-known investor Steve Eisman has publicly criticized Anthropic, stating that the financial data in its prospectus submitted on October 26 only covers up to June, deliberately concealing the latest quarterly information. He cited data showing that Anthropic’s quarterly revenue growth rate sharply dropped from 144% in the second quarter to 45% in the third quarter, indicating a significant slowdown in growth momentum, while the cost structure simultaneously deteriorated.
Crypto prices
More
